IN8bio (INAB) News Today → The Best AI Stock to Own in the World Today is Trading for Just $25 (From Banyan Hill Publishing) (Ad) Free INAB Stock Alerts $1.01 0.00 (0.00%) (As of 05/8/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineIN8bio Doses First Patient in Phase 2 Clinical Trial of INB-400 in Newly Diagnosed Glioblastomaglobenewswire.com - April 30 at 6:05 AMIN8bio Announces Oral Presentation at the Upcoming American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meetingglobenewswire.com - April 24 at 8:00 AMINAB: Initiating Coverage – Enhancing the Insurgents of the Immune Systemfinance.yahoo.com - April 22 at 10:20 AMIN8bio to Present at Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conferenceglobenewswire.com - April 16 at 4:05 PMPromising Preclinical Data Underpins Buy Rating for IN8bio’s nsCAR Platformmarkets.businessinsider.com - April 12 at 5:26 AMAnalysts Offer Insights on Healthcare Companies: TRACON Pharmaceuticals (TCON) and IN8bio (INAB)markets.businessinsider.com - April 10 at 4:20 PMKill Leukemia Cells While Preserving Healthy Tissues: Nano-Cap Cancer Focused Firm IN8bio's Preclinical Candidate Shows Potentialmsn.com - April 10 at 4:20 PMIN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024globenewswire.com - April 9 at 4:30 PMWe're Keeping An Eye On IN8bio's (NASDAQ:INAB) Cash Burn Ratefinance.yahoo.com - March 28 at 11:37 AMLaidlaw sets INAB stock to buy, targets $7.50 priceinvesting.com - March 20 at 12:21 PMINAB Stock Earnings: IN8bio Misses EPS for Q4 2023investorplace.com - March 14 at 10:03 PMIN8bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlightsglobenewswire.com - March 14 at 4:00 PMBuy Recommendation Based on IN8bio’s Promising γ δ T Cell Therapy Developments and Positive Clinical Trial Outcomesmarkets.businessinsider.com - March 13 at 11:50 PMIN8bio to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR Annual Meeting 2024globenewswire.com - March 5 at 4:30 PMIN8bio to Present at Upcoming Investor Conferencesbusinesswire.com - February 26 at 8:00 AMIN8bio, Inc: IN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in Immunologyfinanznachrichten.de - February 14 at 10:37 AMIN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in Immunologyfinance.yahoo.com - February 14 at 10:37 AMIN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in Immunologyglobenewswire.com - February 14 at 8:00 AMAnalysts Are Bullish on These Healthcare Stocks: Adaptimmune Therapeutics (ADAP), CymaBay Therapeutics (CBAY)markets.businessinsider.com - February 13 at 2:33 PMIn8bio stock jumps 11% following clinical updatemsn.com - January 4 at 7:40 PMIN8bio Highlights Recent Company Accomplishments and Outlines 2024 Pipeline Goalsfinance.yahoo.com - January 4 at 9:38 AMIN8bio, Inc. (INAB) Stock Price, News, Quote & History - Yahoo Financeca.finance.yahoo.com - December 18 at 8:50 PMBuy Rating for IN8bio Amidst Promising Leukemia Treatment Advances and Robust Clinical Datamarkets.businessinsider.com - December 14 at 5:19 AMIN8bio Announces Pricing of Financing Totaling up to $46.9 Million in Private Placementfinance.yahoo.com - December 11 at 10:12 AMIN8bio, Inc: IN8bio Appoints Dr. Corinne Epperly to Board of Directorsfinanznachrichten.de - December 7 at 1:20 PMIN8bio Appoints Dr. Corinne Epperly to Board of Directorsfinance.yahoo.com - December 7 at 8:20 AMIN8bio to Host Investor Call at 8:30 AM ET on Tuesday, December 12 to Discuss Updated Clinical Data from Phase 1 Trial of INB-100 in Patients with Leukemiafinance.yahoo.com - December 5 at 8:25 AMHarnessing The Power Of Gamma-Delta T Cells In Cancer Therapy: IN8bio’s Innovative Approachfinance.yahoo.com - November 28 at 1:55 PMHere's Why IN8bio, Inc. (INAB) Could be Great Choice for a Bottom Fisherfinance.yahoo.com - November 23 at 2:06 PMIN8bio, Inc: IN8bio's INB-200 Demonstrates Extended Progression-Free Survival in Patients with Newly Diagnosed Glioblastomafinanznachrichten.de - November 20 at 9:56 AMIN8bio’s INB-200 Demonstrates Extended Progression-Free Survival in Patients with Newly Diagnosed Glioblastomafinance.yahoo.com - November 20 at 9:56 AMPromising Future for IN8bio: Anticipated Data Presentations, Capital Raise, and Innovative Developmentsmarkets.businessinsider.com - November 15 at 1:35 AMIN8bio to Present Data Highlighting Potential of INB-200 and INB-400 to Treat Patients with Newly Diagnosed Glioblastoma Multiforme at Society for Neuro-Oncology 28th Annual Meetingfinance.yahoo.com - November 10 at 10:06 AMIN8bio GAAP EPS of -$0.23msn.com - November 9 at 6:54 PMIN8bio Reports Third Quarter 2023 Financial Results and Provides Corporate Updatefinance.yahoo.com - November 9 at 6:54 PMIN8bio Inc Ordinary Shares INABmorningstar.com - November 8 at 7:52 PMHow IN8bio Is Working To Reach Its Goal Of “Cancer Zero” – Making Cancer A Thing of The Pastfinance.yahoo.com - November 6 at 10:58 AMIN8bio to Present New Positive Data from Phase 1 Trial of INB-100 at 2023 American Society of Hematology (ASH) Annual Meetingtmcnet.com - November 2 at 12:56 PMIN8bio to Participate at the 2023 Truist Securities BioPharma Symposiumfinance.yahoo.com - November 1 at 10:02 AMBuy Recommendation for IN8bio: Anticipated Funding, Clinical Validation, and Key Developments Drive Positive Outlookmarkets.businessinsider.com - October 13 at 3:24 PMAnalyst Maintains Buy Rating for IN8bio Based on Positive SITC Release and Promising R&D Developmentsmarkets.businessinsider.com - September 29 at 9:02 AMIN8bio Announces Presentations at the Society for Immunology of Cancer (SITC) 38th Annual Meetingfinance.yahoo.com - September 29 at 9:02 AMIN8bio to Host Research & Development Day on its Gamma-Delta T cell Therapies on Thursday, October 12, 2023 in New York Cityfinance.yahoo.com - September 26 at 10:00 AMIN8bio director Graff Jeremy acquires 2,500 company sharesseekingalpha.com - September 20 at 8:06 PMIN8bio to Participate at the 2023 Cantor Fitzgerald Global Healthcare Conferencefinance.yahoo.com - September 20 at 8:27 AMIN8bio Strengthens Intellectual Property Portfolio with Newly Granted Global Patentsfinance.yahoo.com - September 19 at 11:21 AMIN8bio to Participate at the H.C. Wainwright 25th Annual Global Investment Conferencefinance.yahoo.com - September 6 at 9:18 AMIN8bio to Present at the H.C. Wainwright Immune Cell Engager Virtual Conferencefinance.yahoo.com - August 15 at 8:59 AMCompanies Like IN8bio (NASDAQ:INAB) Could Be Quite Riskyfinance.yahoo.com - August 13 at 4:47 PMIN8bio (INAB) Gets a Buy from H.C. Wainwrightmarkets.businessinsider.com - August 11 at 6:06 PM Get IN8bio News Delivered to You Automatically Sign up to receive the latest news and ratings for INAB and its competitors with MarketBeat's FREE daily newsletter. Email Address Tech GIANT’s Plans to Revolutionize Crypto… (Ad)A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. INAB Media Mentions By Week INAB Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. INAB News Sentiment▼0.000.37▲Average Medical News Sentiment INAB News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. INAB Articles This Week▼01▲INAB Articles Average Week Get IN8bio News Delivered to You Automatically Sign up to receive the latest news and ratings for INAB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: TARA News Today ENLV News Today INKT News Today SRZN News Today NKGN News Today ACHL News Today PLUR News Today BCLI News Today SABS News Today DYAI News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:INAB) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyElon Musk Secret Crypto Plot ExposedCrypto 101 MediaAI “wealth window” is closing June 25thParadigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingGold Set to EXPLODE!Gold Safe ExchangeCharles Payne Demystifies OptionsUnstoppable ProsperityThe AI Stock that’s Disrupting Every IndustryStockEarnings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IN8bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
